New York Southern Bankruptcy Court

Case number: 1:16-bk-10890 - Defined Diagnostics, LLC - New York Southern Bankruptcy Court

Case Information
Case title
Defined Diagnostics, LLC
Chapter
11
Judge
Michael E. Wiles
Filed
04/12/2016
Last Filing
06/20/2016
Asset
Yes
Vol
v
Docket Header

MDisCs




U.S. Bankruptcy Court
Southern District of New York (Manhattan)
Bankruptcy Petition #: 16-10890-mew

Assigned to: Judge Michael E. Wiles
Chapter 11
Voluntary
Asset


Date filed:  04/12/2016
341 meeting:  05/16/2016

Debtor

Defined Diagnostics, LLC

930 Clopper Road
Gaithersburg, MD 20878
MONTGOMERY-MD
Tax ID / EIN: XX-XXXXXXX
fka
32 Mott Street Acquisition II, LLC

fka
Wellstat Diagonostics, LLC

fka
Wellstat Diagnostics, LLC


represented by
Matthew Freimuth

Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019
212-728-8183
Fax : 212-728-8111
Email: [email protected]

Joseph G. Minias

Willkie Farr & Gallagher, LLP
787 7th Avenue
New York, NY 10019-6099
(212) 728-8000
Fax : (212) 728-8111
Email: [email protected]

Paul V. Shalhoub

Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
(212) 728-8764
Fax : (212) 728-8111
Email: [email protected]

U.S. Trustee

United States Trustee

Office of the United States Trustee
U.S. Federal Office Building
201 Varick Street, Room 1006
New York, NY 10014
(212) 510-0500
 
 

Latest Dockets
Date Filed#Docket Text
06/18/201670Docket Text
Certificate of Mailing Re: Inter-District Transfer (related document(s) (Related Doc # 69)) . Notice Date 06/18/2016. (Admin.) (Entered: 06/19/2016)
06/16/201669Docket Text
Notice of Inter-District Transfer to United States Bankruptcy Court District Of Delaware, Under Case Number 16-11491. (Rodriguez, Maria). (Entered: 06/16/2016)
06/15/201668Docket Text
Order signed on 6/15/2016 transferring case to the District of Delaware due to improper venue. (DePierola, Jacqueline) (Entered: 06/15/2016)
06/10/201667Docket Text
Affidavit of Serviceof Rebecca B. Cordy(related document(s) 62, 59) Filed by Paul V. Shalhoub on behalf of Defined Diagnostics, LLC. (Shalhoub, Paul) (Entered: 06/10/2016)
06/09/201666Docket Text
Transcript regarding Hearing Held on 06/08/16 at 10:16 am RE: PDL BioPharma, Inc.'s objection to use of cash collateral and statement on non-consent to surcharge of collateral Request by PDL BioPharma, Inc. for judicial notice.
Remote electronic access to the transcript is restricted until 9/7/2016.
The transcript may be viewed at the Bankruptcy Court Clerks Office. [Transcription Service Agency: eScribers, LLC.]. (See the Courts Website for contact information for the Transcription Service Agency.). Notice of Intent to Request Redaction Deadline Due By 6/16/2016. Statement of Redaction Request Due By 6/30/2016. Redacted Transcript Submission Due By 7/11/2016. Transcript access will be restricted through 9/7/2016. (Brown, Tenille) (Entered: 06/10/2016)
06/07/201665Docket Text
Affidavit of Service (related document(s) 61, 60) Filed by Matthew K. Kelsey on behalf of PDL Biopharma, Inc.. (Kelsey, Matthew) (Entered: 06/07/2016)
06/07/201664Docket Text
Affidavit of Serviceof Alison R. Ambeault(related document(s) 58) Filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. (Minias, Joseph) (Entered: 06/07/2016)
06/07/201663Docket Text
Affidavit of Serviceof Alison R. Ambeault(related document(s) 53, 49, 52, 51, 50) Filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. (Minias, Joseph) (Entered: 06/07/2016)
06/07/201662Docket Text
Notice of Agendaof Matters Scheduled for Hearing on June 8, 2016 at 10:00 A.M. (Eastern Time)filed by Joseph G. Minias on behalf of Defined Diagnostics, LLC. with hearing to be held on 6/8/2016 at 10:00 AM at Courtroom 617 (MEW) (Minias, Joseph) (Entered: 06/07/2016)
06/06/201661Docket Text
Declarationof Matthew K. Kelsey in Support of PDL Biopharma Inc.'s Omnibus Reply in Support of its (I) Motion to Dismiss the Chapter 11 Case of Defined Diagnostics, LLC (II) Motion for Excusal from Turnover Requirement and (III) Objection to Use of Cash Collateral and Surcharge(related document(s) 60) filed by Matthew K. Kelsey on behalf of PDL Biopharma, Inc.. (Kelsey, Matthew) (Entered: 06/06/2016)